VASCULAR BIOGENICS LTD Sample Clauses

VASCULAR BIOGENICS LTD. (1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
VASCULAR BIOGENICS LTD. CRUCELL HOLLAND B.V. For and on behalf of Crucell N.V. By: /s/ Dxxx Xxxxxx By: /s/ [Illegible] Crucell NV, represented by Or Yxxxxx, Xxxxx 00, 0000 Xxxxxx April 13, 2011 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics [***] Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics
Sample 1
VASCULAR BIOGENICS LTD. For and on behalf of Crucell N.V. By: /s/ Xxxxxx H.P. Xxxx By: /s/ Xxxxxxx Xxxxxxxx Name: Xxxxxx H.P. Xxxx Name: Xxxxxxx Xxxxxxxx Function: President & CEO Function: VP Business Development Leiden, October 3, 2005 Gaithersburg, September 20, 2005 BioReliance Ltd. By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Function: Global Leader Manufacturing Glasgow, September 19, 2005 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics [***]
Sample 1
VASCULAR BIOGENICS LTD. For and on behalf of Crucell N.V. Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics By: /s/ [Illegible] By: /s/ Xxxx Xxxxxxxxx Name: Name: Xxxx Xxxxxxxxx Function: Function: VP Research Xxxxx Xxxxxxx Inc. By: /s/ J. Xxxxx Xxxxx, Xx. /s/ [Illegible] Name: J. Xxxxx Xxxxx, Xx. VP Strategy & Corporate Development Function: Head, Viral-based Therapeutics Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics ATTACHMENT 1 STATEMENT OF WORK Quotations: [***]
Sample 1
VASCULAR BIOGENICS LTD. CRUCELL HOLLAND B.V. For and on behalf of Crucell N.V. By: /s/ Xxxx Xxxxxx By: /s/ [Illegible] Crucell NV, represented by Or Xxxxxx, Xxxxx 00, 0000 Xxxxxx April 13, 2011 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Exhibit 1.18 — Cell Line Designation: PER.C6® Origin of the Cell Line PER.C6® cells are [***] transformed with [***] of [***] The estimated copy number is [***] The [***] in the construct is driven by the [***] The [***] are derived from [***] Cell Line Passage History Research Master Cell Bank [***] was stored at passage number [***] on 17 January 1996. Research Working Cell Bank [***] was generated from [***] and stored at passage number [***] on 7 February 1996. The cell banks are stored in the [***] of [***] at [***] in [***] Components Used For Culture of the Cells [***] with [***] and, optionally, [***]. [***] was used for [***] Quality Control All work on the development of PER.C6® cells carried out at Crucell Holland has been carried out under controlled conditions. The data have been reviewed by QA Crucell Holland. The research Master Cell Bank and research Working Cell Bank have been tested by GLP-inspected contract testing companies. All recorded data mentioned have been reviewed by Quality Assurance, Crucell Holland BV, Leiden. All final reports have been reviewed for compliance to the specifications and pertinent relevant regulatory requirements from the US and EEC. Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics Safety Tests on the PER.C6® Human Adenoviral Packaging cell Line Research Master Cell Bank Test Result [***] [***] Research Working Cell Bank Test Result [***] [***] Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. Commercial License Agreement PER.C6® Crucell Holland – Vascular Biogenics
Sample 1
VASCULAR BIOGENICS LTD registration number 50-000000-0 a company incorporated in Israel and having its principal place of business at 6 Xxxxx Xxxxxxxxx St. Or-Yxxxxx Israel (the “Customer”) AND Biopharmax Group Ltd. registration number 50-000000-0, a private company incorporated in Israel and having its principal place of business at 4 Xxxxxxxxx Xx. Xxxxxxxxx (the “Contractor”)
Sample 1

Related to VASCULAR BIOGENICS LTD

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • COVID-19 Residents acknowledge that in March 2020 the World Health Organization declared a global pandemic of the virus leading to COVID-19. The Governments of Canada, the Province of Ontario, and local Governments responded to the pandemic with legislative amendments, controls, orders, by-laws, requests of the public, and requests and requirements to Humber (collectively, the “Directives”). It is uncertain how long the pandemic, and the related Directives, will continue, and it is unknown whether there may be a resurgence of the virus leading to COVID-19 or any mutation thereof (collectively, “COVID- 19”). Without limiting the generality of the foregoing paragraph, Humber shall not be held legally responsible or be deemed to be in breach of this Agreement for any damages or loss arising out of or caused by:

  • Third Party Technology Customer is hereby notified that third parties have licensed certain technology to Company, which is contained in the Software. Notwithstanding anything herein to the contrary, Customer hereby consents to the disclosure of Customer’s identity, and such other terms of this Agreement as necessary, to such third party licensors for the purpose of enabling Company to comply with the terms and conditions of such third party licenses. Any such Customer information will be provided pursuant to an obligation of confidentiality and nondisclosure at least as stringent as that imposed by this Agreement.

  • Nepotism No employee shall be awarded a position where he/she is to be directly supervised by a member of his/her immediate family. “

  • Motorola s sole obligation to Licensee and Licensee’s exclusive remedy under this warranty is to use reasonable efforts to remedy any material Software defect covered by this warranty. These efforts will involve either replacing the media or attempting to correct significant, demonstrable program or documentation errors or Security Vulnerabilities. If Motorola cannot correct the defect within a reasonable time, then at Motorola’s option, Motorola will replace the defective Software with functionally-equivalent Software, license to Licensee substitute Software which will accomplish the same objective, or terminate the license and refund the Licensee’s paid license fee.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • EMERGING TECHNOLOGIES The State reserves the right to modify the terms of this Contract or any future Periodic Recruitments, to allow for emerging technologies. OGS reserves the right to include such technology(ies) hereunder or to issue a formal modification or amendment to this Contract.

Time is Money Join Law Insider Premium to draft better contracts faster.